CDH1 and prostate cancer: The role of E-cadherin as a tumor suppressor is supported by the frequently observed loss of this molecule in a variety of invasive cancers, including breast [51], ovarian [8], pancreatic [52], gastric [53] and prostate cancer [54, 55].